ATNAUJINIMAS Hematologija / onkologija 2024 m
ESMO kongresas 2023 m
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
You're using an older version of your web browser, so some features may not display properly.
MINIMALŪS reikalavimai: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.Access to resources.
OncologyPRO dabar siūlo susitikimų išteklius: +3.000 XNUMX skaidrių ir internetinių transliacijų; santraukos ir el. plakatai.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Daily Reporter177Lu PSMA-617 pagerina rPFS pacientams, sergantiems metastazavusiu kastracijai atspariu prostatos vėžiu, kurie nenaudojo taksanų 23 m. spalio 2023 d.
Registruokitės bilietams ar kasoms
Vietos žemėlapis ir viešbučiai aplinkui
Miunchenas – Holiday Inn Munich – miesto centras, Bavarija, Vokietija Miunchenas – Holiday Inn Munich – miesto centras, Bavarija, Vokietija
Prenumeruok